Clover Corporation Limited · ASX:CLV
Clover — Investor Presentation (March 2022)
13 slides from Clover's investor presentation, Mar 16, 2022
Slide 1: Managing Director Report 6 Months to 31 Jan 2022
Managing Director Report 6 Months to 31 Jan 2022 16 March 2022
Slide 2: Vision, Values and Purpose Statement
Vision, Values and Purpose Statement Vision To optimise the health and development of adults, infants and children. Values Respect, Response, Responsibility Purpose In collaboration with key market participants, Clover develops customised high value nutritional ingredients that enhance the wellbeing
Slide 3: Half Year FY'22 Performance Highlights
Half Year FY’22 Performance Highlights ♣ Total half year Revenue ♣ Operating Expenses $29.7m up 1.0% on $5.9m up 28.3% (1HFY21 1HFY21 $29.4m $4.6m) with continued focus on R&D development and ♣ NPAT $2.0m down ongoing legal engagement 20.0% on 1HFY21 $2.5m ♣ Clover listed in Chinese GB ♣ Underlying
Slide 4: COVID-19 Update
COVID-19 Update ♣ Clover has continued managing the business to our COVID-19 safe plan with the focus on the health and safety of our employees, customers and suppliers ♣ Freight conditions for import and export have disrupted supply and increased costs ♣ Clover maintains a high inventory position t
Slide 5: Sales by Geography
Sales by Geography 1H22 Sales by Market Americas 8% Europe Europe ♣ European sales are similar to 1H FY21 with COVID- 15% Australia/NZ 19 conditions continuing to make new product 34% development difficult Asia ANZ ♣ Sales into Asia have improved compared to the prior year. Asia 43% ♣ AU / NZ contin
Slide 6: Half Year 2022 Results
Half Year 2022 Results ♣ Revenue stable coming off the pantry stacking of 18 months ago but still impeded by COVID-19 conditions AUD million 4D Reported 4D Reported 31 Jan 2022 31 Jan 2021 ♣ Infant formula customers Revenue $29.7 $29.4 markets have been affected by COVID-19 restrictions, China marke
Slide 7: Balance Sheet 31 January 2022
Balance Sheet 31 January 2022 AUD Reported Reported 31 Jan 2022 31 Jul 2021 Movement $M $M $M ♣ Cash balance remains strong Cash 8.0 9.1 (1.1) $8.0m Trade Receivables 13.4 13.3 0.1 Inventories 32.3 30.8 1.5 ♣ Trade receivables consistent on Total Current Assets 54.5 54.7 (0.2) comparative sales Non
Slide 8: An Update on Growth Platforms: Focus on Infant Formula
An Update on Growth Platforms Focus on Infant Formula New New Product Market Development Development 7
Slide 9: Growth Platforms: Market Development - Diversification & Applications
Growth Platforms Market Development- Diversification & Applications UHT applications Extended shelf-life (Gelphorm® dairy base drink microencapsulated (Driphorm 50% algal algal/fish oil powder): 125mg / emulsion): 125mg 250ml serve DHA / 250ml serve Gummies Sports bars (Driphorm (Hypoallergenic 50%
Slide 10: Growth Platform: Expanding our market reach
Growth Platform Expanding our market reach ♣ New products will be trialled with customers in the 2HFY22 aimed at expanding markets the company serves such as Medical Foods, General Food & Drinks and Nutraceuticals. ♣ R&D business moved to an expanded facility capable of supporting additional people
Slide 11: Growth Platform: Focus on Infant Formula
Focus on Infant Growth Platform Formula Infant formula provides new opportunities ♣ Clover has increased its customer base across Europe and China with Infant Formula manufacturers ♣ Clover has achieved initial orders into Chinese Infant formula manufacturers ♣ Clover products are qualified with sev
Slide 12: 2HFY22 Outlook & Priorities
2HFY22 Outlook & Priorities ♣ Maintain the Heath & Safety focus on our employees, suppliers, customers and stakeholders ♣ Deploy new products to establish the segments of Pharmaceuticals/Medical foods, Nutraceuticals and Foods ♣ Supply chain challenges remain a focus on obtaining raw materials and e
Slide 13: Disclaimer
Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions. This